Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
IPO Year: 2019
Exchange: NASDAQ
Website: vir.bio
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/29/2024 | $23.00 → $9.00 | Overweight → Neutral | JP Morgan |
9/8/2023 | $23.00 → $14.00 | Buy → Neutral | BofA Securities |
3/6/2023 | $35.00 → $34.00 | Neutral → Overweight | JP Morgan |
2/21/2023 | $41.00 → $53.00 | Neutral → Buy | Goldman |
1/27/2023 | $18.00 → $30.00 | Underweight → Equal-Weight | Morgan Stanley |
9/14/2022 | $40.00 | Outperform | SVB Leerink |
9/9/2022 | $15.00 | Underweight | Morgan Stanley |
3/3/2022 | $36.00 → $28.00 | Underperform → Neutral | Baird |
3/3/2022 | $36.00 → $28.00 | Underperform → Neutral | Robert W. Baird |
12/21/2021 | $36.00 | Neutral → Underperform | Robert W. Baird |
JP Morgan downgraded Vir Biotechnology from Overweight to Neutral and set a new price target of $9.00 from $23.00 previously
BofA Securities downgraded Vir Biotechnology from Buy to Neutral and set a new price target of $14.00 from $23.00 previously
JP Morgan upgraded Vir Biotechnology from Neutral to Overweight and set a new price target of $34.00 from $35.00 previously
Goldman upgraded Vir Biotechnology from Neutral to Buy and set a new price target of $53.00 from $41.00 previously
Morgan Stanley upgraded Vir Biotechnology from Underweight to Equal-Weight and set a new price target of $30.00 from $18.00 previously
SVB Leerink initiated coverage of Vir Biotechnology with a rating of Outperform and set a new price target of $40.00
Morgan Stanley initiated coverage of Vir Biotechnology with a rating of Underweight and set a new price target of $15.00
Baird upgraded Vir Biotechnology from Underperform to Neutral and set a new price target of $28.00 from $36.00 previously
Robert W. Baird upgraded Vir Biotechnology from Underperform to Neutral and set a new price target of $28.00 from $36.00 previously
Robert W. Baird downgraded Vir Biotechnology from Neutral to Underperform and set a new price target of $36.00